Rheumatology Clinic, Prof. Dr Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.
Rheumatology Clinic, Ümraniye Research and Training Hospital, Istanbul, Turkey.
Int J Rheum Dis. 2022 Nov;25(11):1239-1245. doi: 10.1111/1756-185X.14407. Epub 2022 Jul 29.
To determine the factors associated with colchicine resistance and the effect of colchicine resistance on health-related quality of life (QoL) in patients with familial Mediterranean fever (FMF).
Demographic and clinical features, MEFV gene mutations, and Pras disease severity scores were recorded. QoL was assessed using the Short Form-36 (SF-36) and FMF-QoL scales. Colchicine resistance was defined as at least 1 attack per month for 6 months at the maximum tolerated dose of colchicine in fully compliant patients.
The mean age of 118 patients (90 female, 28 male) with FMF was 38.4 ± 12.5 years. The percentage of colchicine-resistant patients was 19.5%. In univariable analysis, smoking (odds ratio [OR] = 2.885; 95% confidence interval [CI] = 1.104-7.539; P = 0.031), attack duration (OR = 1.955; 95% CI = 1.137-3.360; P = 0.015), presence of arthritis (OR = 5.235; 95% CI = 1.508-18.179; P = 0.009), and disease severity score (OR = 1.790; 95% CI = 1.334-2.402; P < 0.001) were associated with colchicine resistance. The FMF-QoL and subscales of SF-36 except for role emotional and vitality, were different between colchicine-resistant and non-resistant patients (P < 0.05).
Smoking, attack duration, presence of arthritis, and disease severity were associated with colchicine resistance in fully compliant FMF patients. Colchicine-resistant patients had poorer health-related QoL.
确定与秋水仙碱耐药相关的因素,以及秋水仙碱耐药对家族性地中海热(FMF)患者健康相关生活质量(QoL)的影响。
记录人口统计学和临床特征、MEFV 基因突变和普拉兹疾病严重程度评分。使用 36 项简短健康调查问卷(SF-36)和 FMF-QoL 量表评估 QoL。秋水仙碱耐药定义为完全依从的患者在最大耐受剂量的秋水仙碱下,每月至少发作 1 次,持续 6 个月。
118 例 FMF 患者(90 例女性,28 例男性)的平均年龄为 38.4±12.5 岁。秋水仙碱耐药患者的比例为 19.5%。在单变量分析中,吸烟(比值比 [OR] = 2.885;95%置信区间 [CI] = 1.104-7.539;P = 0.031)、发作持续时间(OR = 1.955;95% CI = 1.137-3.360;P = 0.015)、关节炎存在(OR = 5.235;95% CI = 1.508-18.179;P = 0.009)和疾病严重程度评分(OR = 1.790;95% CI = 1.334-2.402;P<0.001)与秋水仙碱耐药相关。FMF-QoL 和 SF-36 的除角色情感和活力以外的子量表在秋水仙碱耐药和非耐药患者之间存在差异(P<0.05)。
在完全依从的 FMF 患者中,吸烟、发作持续时间、关节炎存在和疾病严重程度与秋水仙碱耐药相关。秋水仙碱耐药患者的健康相关 QoL 较差。